Table of contents

• Clinical trials overview
• Pediatric study in chronic kidney disease
• Cardiometabolism study
• Study design and main measures
• Who the trials are for
• Key terms explained

Clinical trials overview

These clinical trials are studying Roxadustat in different patient groups and for different health problems.^[1][2] Both studies are Phase 3 and are listed as Authorised.^[1][2] One trial focuses on anemia in children and adolescents with chronic kidney disease, and the other focuses on cardiometabolic risk in people with cardiovascular disease risk factors and metabolic syndrome.^[1][2]

Pediatric study in chronic kidney disease

The pediatric study is an open-label, uncontrolled Phase 3 trial for participants with anemia associated with chronic kidney disease.^[2] It includes children and adolescents, and the brief summary says the goal is to evaluate the activity of Roxadustat for treating anemia in this group.^[2]

This trial plans to enroll 104 participants.^[2] The main outcome is the change in hemoglobin from the start of treatment to the average level during treatment weeks 20 to 24.^[2] The treatment period is described as 24 weeks, with 4 weeks of fixed dose treatment followed by 20 weeks of dose titration, which means the dose is adjusted over time.^[2]

Cardiometabolism study

The second trial is a Phase 3 interventional study called Effect of Roxadustat on Cardiometabolism.^[1] It studies people with risk factors of cardiovascular disease and metabolic syndrome.^[1] The brief summary says the study is looking at the effects of Roxadustat on glucose and lipid metabolism and on cardiovascular function.^[1]

This study plans to enroll 24 participants.^[1] Its primary outcome is plasma total cholesterol levels.^[1] The intervention list includes placebo and Roxadustat, which shows that the study is comparing treatment conditions.^[1]

Study design and main measures

Both trials are designed to measure specific results, called endpoints, so researchers can judge the effect of Roxadustat in each study population.^{[1][2] In the pediatric trial, the key endpoint is hemoglobin change, which helps show whether anemia is improving.[2] In the cardiometabolism trial, the key endpoint is total cholesterol in plasma, which helps show changes in blood fat levels.[1]}

The trial data also show different study styles.^{[1][2] One study is open-label and uncontrolled, while the other includes placebo, so the research designs are not the same.[1][2]}

Who the trials are for

The pediatric trial is for children and adolescents with anemia linked to chronic kidney disease.^[2] The cardiometabolism trial is for people with cardiovascular risk factors and metabolic syndrome.^[1] These groups are different, so the studies are not asking the same question in the same type of patient.^[1][2]

• Children and adolescents with chronic kidney disease: this group is studied to see whether Roxadustat helps anemia improve over time.^[2]

• People with cardiometabolic risk: this group is studied to see whether Roxadustat affects cholesterol, glucose and lipid metabolism, and cardiovascular function.^[1]

Key terms explained

Chronic kidney disease means a long-term kidney problem.^[2] Anemia means the blood has too little hemoglobin, so it may carry less oxygen.^[2] Metabolic syndrome is a group of health problems that raise the risk of heart disease and diabetes.^[1] Cardiovascular function refers to how the heart and blood vessels work.^[1]